

Xing-Sheng Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5579251/publications.pdf>

Version: 2024-02-01

26
papers

335
citations

1039406

9
h-index

887659

17
g-index

30
all docs

30
docs citations

30
times ranked

452
citing authors

#	ARTICLE	IF	CITATIONS
1	Allele Frequencyâ€“Adjusted Blood-Based Tumor Mutational Burden as a Predictor of Overall Survival for Patients With NSCLC Treated With PD-(L)1 Inhibitors. <i>Journal of Thoracic Oncology</i> , 2020, 15, 556-567.	0.5	66
2	Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 247-254.	1.1	48
3	Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2427-2433.	1.2	41
4	Routine-Dose and High-Dose Icotinib in Patients with Advanced Nonâ€“Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial. <i>Clinical Cancer Research</i> , 2020, 26, 3162-3171.	3.2	16
5	The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study. <i>PLoS ONE</i> , 2015, 10, e0142500.	1.1	14
6	First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2020, 13, 6.	6.9	13
7	Circulating tumor cells (<sc>CTCs</sc>)/circulating tumor endothelial cells (<sc>CTECs</sc>) and their subtypes in small cell lung cancer: Predictors for response and prognosis. <i>Thoracic Cancer</i> , 2021, 12, 2749-2757.	0.8	12
8	Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. <i>Thoracic Cancer</i> , 2021, 12, 2585-2593.	0.8	12
9	Apatinib, a novel VEGFR inhibitor plus docetaxel in advanced lung adenocarcinoma patients with wild-type EGFR: a phase I trial. <i>Investigational New Drugs</i> , 2019, 37, 731-737.	1.2	11
10	Real world study of regimen containing bevacizumab as firstâ€“line therapy in Chinese patients with advanced nonâ€“small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 805-813.	0.8	10
11	Superior efficacy of immunotherapyâ€“based combinations over monotherapy for EGFR â€“mutant nonâ€“small cell lung cancer acquired resistance to EGFRâ€“TKIs. <i>Thoracic Cancer</i> , 2020, 11, 3501-3509.	0.8	9
12	Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. <i>Thoracic Cancer</i> , 2021, 12, 2924-2932.	0.8	9
13	The commensal consortium of the gut microbiome is associated with favorable responses to anti-programmed death protein 1 (PD-1) therapy in thoracic neoplasms. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	1.4	9
14	Gemcitabine combined with cisplatin as adjuvant chemotherapy for nonâ€“small cell lung cancer: <sc>A</sc> retrospective analysis. <i>Thoracic Cancer</i> , 2017, 8, 482-488.	0.8	7
15	Population Pharmacokinetics and Exposureâ€“Safety Relationship of Paclitaxel Liposome in Patients With Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1731.	1.3	7
16	Hyaluronic Acid Correlates With Bone Metastasis and Predicts Poor Prognosis in Small-Cell Lung Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 785192.	1.5	5
17	Efficacy and safety profile of combining programmed cell deathâ€“1 (<sc>PD</sc>â€“1) inhibitors and antiangiogenic targeting agents as subsequent therapy for advanced or metastatic nonâ€“small cell lung cancer (<sc>NSCLC</sc>). <i>Thoracic Cancer</i> , 2021, 12, 2360-2368.	0.8	4
18	Different responses to antiâ€“programmed cell death protein 1 (PDâ€“1) immunotherapy in a patient with Lynch syndrome and metachronous urothelial and colon cancer: A case report. <i>Oncology Letters</i> , 2019, 18, 5085-5090.	0.8	4

#	ARTICLE	IF	CITATIONS
19	The clinical significance of RET gene fusion among Chinese patients with lung cancer. <i>Translational Cancer Research</i> , 2020, 9, 6455-6463.	0.4	4
20	Combination TSO plus EGFR tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR TKIs: A phase II, single-arm trial. <i>Thoracic Cancer</i> , 2018, 9, 693-698.	0.8	3
21	Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2018, 9, 1716-1724.	0.8	3
22	Progression pattern and post-progression treatment of furmonertinib (AST2818) in EGFR T790M mutation positive NSCLC patients: A post-hoc analysis from a multicenter, single-arm study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21071-e21071.	0.8	0
23	Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma. <i>Chinese Medical Journal</i> , 2021, 134, 2119-2121.	0.9	0
24	Phase I study of apatinib combined with docetaxel in EGFR-negative advanced non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2018, 36, e21184-e21184.	0.8	0
25	BPI-9016M, a novel c-Met inhibitor, in pretreated advanced solid tumor: Results from a first-in-human, phase I, dose-escalation study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21108-e21108.	0.8	0
26	CD56+ lymphoepithelioma-like carcinoma of the lung: A case report and literature review. <i>World Journal of Clinical Cases</i> , 2020, 8, 1257-1264.	0.3	0